Anavex Life Sciences (AVXL) is a publicly traded Healthcare sector company. As of May 21, 2026, AVXL trades at $2.75 with a market cap of $266.89M and a P/E ratio of -4.95. AVXL moved +3.00% today. Year to date, AVXL is -30.38%; over the trailing twelve months it is -63.48%. Its 52-week range spans $2.61 to $14.44. Analyst consensus is buy with an average price target of $20.00. Rallies surfaces AVXL's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Anavex Names Interim CEO Kellmeyer, Signals Q1 Filing Delay: Anavex Life Sciences named Terrie Kellmeyer, PhD, as interim CEO after board-requested resignation of Christopher Missling and signaled a Form 12b-25 filing to delay its March quarter 10-Q submission. Management emphasized its robust cash position, lack of long-term debt, and continued focus on oral blarcamesine for early Alzheimer’s disease.
| Metric | Value |
|---|---|
| Price | $2.75 |
| Market Cap | $266.89M |
| P/E Ratio | -4.95 |
| EPS | $-0.54 |
| Dividend Yield | 0.00% |
| 52-Week High | $14.44 |
| 52-Week Low | $2.61 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $4.68M |
| Net Income | $-46.38M |
| Gross Margin | 0.00% |
2 analysts cover AVXL: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $20.00.